Cyfuse Biomedical
Tissue fabrication systems and cell-based products in japan and internationally.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | N/A | IPO |
| Total Funding | 000k | ||
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 415 % | (47 %) | (84 %) | (11 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (210 %) | 24 % | (94 %) | (881 %) | (1514 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (240 %) | 20 % | (127 %) | (964 %) | (1602 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cyfuse Biomedical is a pioneering company in the field of regenerative medicine, leveraging advanced 3D bioprinting technology to develop innovative medical solutions. The company operates primarily in the healthcare and biotechnology markets, focusing on creating products that aid in the regeneration of tissues and organs. Cyfuse's core clients include research institutions, hospitals, and biotech firms that are engaged in cutting-edge medical research and clinical applications.
The business model revolves around the development and commercialization of 3D bioprinters and related consumables, which are sold to medical and research facilities. Additionally, Cyfuse generates revenue through collaborative research agreements and licensing of its proprietary technology. The company's unique approach combines biology and engineering to create a platform that significantly advances the field of cellular medicine, offering new treatment options and improving patient outcomes.
Keywords: 3D bioprinting, regenerative medicine, tissue engineering, cellular therapy, biotechnology, medical research, clinical applications, healthcare innovation, bioprinters, proprietary technology.